PT89916A - Processo para a producao de proteinas modificadas - Google Patents

Processo para a producao de proteinas modificadas

Info

Publication number
PT89916A
PT89916A PT89916A PT8991689A PT89916A PT 89916 A PT89916 A PT 89916A PT 89916 A PT89916 A PT 89916A PT 8991689 A PT8991689 A PT 8991689A PT 89916 A PT89916 A PT 89916A
Authority
PT
Portugal
Prior art keywords
amino acids
production
modified proteins
mutants
leu
Prior art date
Application number
PT89916A
Other languages
English (en)
Other versions
PT89916B (pt
Inventor
Markus Gerhard Grutter
Manfred Liersch
Dirk Heinz
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of PT89916A publication Critical patent/PT89916A/pt
Publication of PT89916B publication Critical patent/PT89916B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Pest Control & Pesticides (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
PT89916A 1988-03-07 1989-03-06 Processo para a producao de proteinas modificadas PT89916B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH84088 1988-03-07

Publications (2)

Publication Number Publication Date
PT89916A true PT89916A (pt) 1989-11-10
PT89916B PT89916B (pt) 1994-05-31

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
PT89916A PT89916B (pt) 1988-03-07 1989-03-06 Processo para a producao de proteinas modificadas

Country Status (20)

Country Link
US (1) US5079229A (pt)
EP (1) EP0332576B1 (pt)
JP (1) JP2716191B2 (pt)
KR (1) KR0134377B1 (pt)
AT (1) ATE103930T1 (pt)
AU (1) AU623881B2 (pt)
CA (1) CA1339105C (pt)
DD (1) DD283645A5 (pt)
DE (1) DE58907373D1 (pt)
DK (1) DK107389A (pt)
ES (1) ES2063161T3 (pt)
FI (1) FI96116C (pt)
HU (1) HU209401B (pt)
IE (1) IE62993B1 (pt)
IL (1) IL89496A0 (pt)
NO (1) NO178870C (pt)
NZ (1) NZ228208A (pt)
PT (1) PT89916B (pt)
TW (1) TW211522B (pt)
ZA (1) ZA891679B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
EP0929577B1 (en) 1996-09-24 2003-06-04 The Procter & Gamble Company Stabilized proteinaceous protease inhibitors and variants thereof
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
CA1297437C (en) * 1983-11-21 1992-03-17 Hans Rink Process for the preparation of protease inhibitors
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
EP0164719B1 (en) * 1984-06-14 1992-05-06 Chiron Corporation Active site modified protease alpha-1-antitrypsin inhibitors and their production
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
DE58907373D1 (de) 1994-05-11
TW211522B (pt) 1993-08-21
HUT50503A (en) 1990-02-28
EP0332576B1 (de) 1994-04-06
NO890932L (no) 1989-09-08
DK107389D0 (da) 1989-03-06
KR0134377B1 (ko) 1998-04-20
AU623881B2 (en) 1992-05-28
ATE103930T1 (de) 1994-04-15
FI891020A (fi) 1989-09-08
EP0332576A2 (de) 1989-09-13
NZ228208A (en) 1990-08-28
ES2063161T3 (es) 1995-01-01
FI96116B (fi) 1996-01-31
AU3095989A (en) 1989-09-07
NO178870C (no) 1996-06-19
EP0332576A3 (en) 1990-09-12
NO178870B (no) 1996-03-11
NO890932D0 (no) 1989-03-06
JPH029392A (ja) 1990-01-12
DK107389A (da) 1989-09-08
IE890719L (en) 1989-09-07
CA1339105C (en) 1997-07-29
FI891020A0 (fi) 1989-03-03
IL89496A0 (en) 1989-09-10
DD283645A5 (de) 1990-10-17
ZA891679B (en) 1989-10-25
FI96116C (fi) 1996-05-10
KR890014735A (ko) 1989-10-25
JP2716191B2 (ja) 1998-02-18
IE62993B1 (en) 1995-03-08
HU209401B (en) 1994-05-30
US5079229A (en) 1992-01-07
PT89916B (pt) 1994-05-31

Similar Documents

Publication Publication Date Title
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
DE59006837D1 (de) Verfahren zur fermentativen Herstellung von Aminosäuren, insbesondere L-Lysin, dafür geeignete Mikroorganismen und rekombinante DNA.
BR9407820A (pt) Processo para produçao de um concentrado de proteina enriquecido com aglucono isoflavonas a partir de um material de proteina vegetal concentrado de proteina enriquecido com aglucono isoflavona concentrado de proteina enriquecido com aglucono isoflavona e processo para recuperação em um concentrado de proteina pelo menos 50% de uma isoflavona em um material de proteina vegetal
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
ATE195148T1 (de) Prozess zur rekombinanten herstellung von hiv-2 - proteinen sowie zellen, die hiv-2 - proteine exprimiert
ES2065911T3 (es) Produccion de proteinas en formas activas.
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
PT89916A (pt) Processo para a producao de proteinas modificadas
HU895788D0 (en) Process for producing peptides and medical products containing them
MY103362A (en) Production of proteins in active forms
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
ES2170144T3 (es) Variantes que no se empalman de gp350/220.
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
DE3853092D1 (de) Verfahren zur Herstellung von Proteinen, die nicht in Proteinen vorkommende Aminosäuren enthalten.
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
EP0288057A3 (en) Des-19-leucine, 20-glutamine, 21-threonine, 22-tyrosine-calcitonin
HUT37109A (en) Process for the phosphinoylation of amino gropus of amino-acids, peptides and esters thereof

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19931118

PC3A Transfer or assignment

Free format text: 970410 NOVARTIS AG CH

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20030531